Skip to content

Dogwood Therapeutics DWTX Temporary Equity Accrual Of Paid In Kind Dividends

Temporary Equity Accrual Of Paid In Kind Dividends at other companies

Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$1.1M-16.5%
Redwire logo
RedwireRDW
$1.51M-57.2%
ATN International logo
ATN InternationalATNI
$1.53M+9.0%
BAE
Bridger Aerospace Group Holdings, Inc.BAER
$7.03M+7.1%
Beneficient logo
BeneficientBENF
$3.05M+21.0%
Grove Collaborative Holdings logo
Grove Collaborative HoldingsGROV
$375K0.0%

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0.0×
Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept dwtx:TemporaryEquityAccrualOfPaidInKindDividends.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's temporary equity accrual of paid in kind dividends.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's temporary equity accrual of paid in kind dividends?
Dogwood Therapeutics (DWTX) reported temporary equity accrual of paid in kind dividends of -$1.26M in Q1 2025.
How has Dogwood Therapeutics's temporary equity accrual of paid in kind dividends changed year-over-year?
Dogwood Therapeutics's temporary equity accrual of paid in kind dividends decreased by 877.7% year-over-year, from -$128.53K to -$1.26M.
What does temporary equity accrual of paid in kind dividends mean?
This metric measures the accrual of dividends that are paid in the form of additional equity securities rather than cash. It represents a non-cash financing activity that increases the company's equity obligations to shareholders over time. Tracking this is essential for assessing the impact of non-cash dividend policies on shareholder dilution and capital structure.